Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Funding Boom Time Continues For UK Life Sciences

Accounted For 60% Of Biotech Venture Capital Invested In Europe

Executive Summary

Nearly £1.6bn was invested in the pharma, biotech and life sciences sector in the UK from March to May, which means £2.39bn has been raised in the year to date, more than in the whole of 2020.

You may also be interested in...



Eli Lilly To Explore MiNA's Small Activating RNA Technology

Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.

NeRRe: Advancing Neurokinin Receptor Antagonists

Starting the year with a cash injection of £23m, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. CEO Mary Kerr spoke to Scrip's Mike Ward at the 2017 Biotech Showcase in San Francisco.

Leqvio Launch Will Be Fundamental To Success Of New Novartis

Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel